GlassScriptPhysician profile
Brenda Knowles
NPI 1689029837
$7,724.29
in general payments reported to CMS, 2019-2025
38 companies · $2,337 in 2025
The $2,337 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $384 · 2022: $1,036 · 2023: $1,615 · 2024: $2,353 · 2025: $2,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,213 · Education: $91.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,212.98 |
| Education | $91.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,683.31 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $899.65 | 2022-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Pfizer INC. | $768.72 | 2022-2025 | |
| Lundbeck LLC | $411.81 | 2023-2025 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $263.65 | 2022 | |
| Ucb, INC. | $256.56 | 2021-2025 | Briviact, Fintepla, Rystiggo |
| Astrazeneca Pharmaceuticals LP | $254.74 | 2021-2025 | Wainua |
| Axsome Therapeutics, INC. | $223.95 | 2025 | Symbravo |
| Lilly USA, LLC | $216.81 | 2022-2023 | Reyvow, Emgality |
| Neurocrine Biosciences, INC. | $203.27 | 2024-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $140.19 | 2021 | |
| Neurelis, INC. | $139.61 | 2022-2023 | Valtoco |
| Jazz Pharmaceuticals INC. | $136.46 | 2023-2025 | |
| Tanabe Pharma America, INC. | $120.92 | 2024-2025 | Radicava |
| Kyowa Kirin, INC. | $117.96 | 2022-2024 | Nourianz |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brenda Knowles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.